- Home
- RXST
RXST
RxSight Inc.
as 05-30-2025 4:00pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 1.0B | IPO Year: | 2021 |
| Target Price: | $39.30 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.53 - $61.10 | Next Earning Date: | 05-07-2025 |
| Revenue: | $148,310,000 | Revenue Growth: | 46.70% |
| Revenue Growth (this year): | 22.25% | Revenue Growth (next year): | 18.58% |
Stock Insider Trading Activity of RxSight Inc. (RXST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fountain Tamara | RXST | Director | Mar 12 '25 | Sell | $25.71 | 7,000 | $180,001.50 | 24,793 |
Latest RxSight Inc. News
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
TipRanks
18 hours ago
Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks
Zacks
9 days ago
Do Options Traders Know Something About RxSight Stock We Don't?
GlobeNewswire
11 days ago
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
Insider Monkey
12 days ago
Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued
MT Newswires
12 days ago
RxSight Shares Rise After Upgrade From Wells Fargo
MT Newswires
13 days ago
Wells Fargo Upgrades RxSight to Overweight From Equalweight, Lifts Price Target to $25 From $17
MT Newswires
18 days ago
Medical Technology Firms Face Price Target Revisions From Morgan Stanley
MT Newswires
19 days ago
Morgan Stanley Adjusts Price Target on RxSight to $20 From $42, Maintains Overweight Rating
Compare RXST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.